Merck (MRK) Reports Positive Opinion from EMA for KEYTRUDA (pembrolizumab) Combination with Pemetrexed & Platinum Chemotherapy
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
